The Fly | DFTX

May 7th, 2026

Summary

Earnings Call Date:: 2026-05-07
Change Since:: +93.06%
Next Earnings Date:: 2026-08-06

Earnings Call Sentiment

Positive

The call emphasizes strong clinical momentum (multiple Phase III programs with imminent topline readouts, Breakthrough Therapy designation in GAD, high statistical power in key studies), a clear commercialization plan and a solid cash position ($373.4M runway into 2028). These positives are tempered by materially higher operating expenses and a sizable YOY increase in net loss (driven by program investment and a non-cash warrant valuation change), design-related placebo risk from Phase II, and remaining regulatory and payer uncertainties that could affect timing and labeling. On balance, management’s message is forward-looking and execution-focused with meaningful near-term inflection points.

Company Guidance

The company reiterated near-term clinical and financial guidance: three pivotal DT120 toplines are expected imminently—EMERGE (MDD, enrollment 149) later this quarter with a 6‑week primary endpoint, VOYAGE (GAD, enrollment 214) expected early Q3 and PANORAMA (GAD, >200 enrolled) expected late Q3 with 12‑week primaries—and a planned HAVEN PTSD study in 2027; VOYAGE and PANORAMA are now powered at ≥99% to detect a 5‑point placebo‑adjusted difference (EMERGE was powered at 80% with significance possible at ~3 points), the Phase III program targets durability of a single administration for at least 12 weeks (Part B follows patients up to one year and allows up to four additional open‑label treatments), Phase II showed 12‑week durability at 100 µg, and DT120 holds Breakthrough Therapy designation in GAD; financially Q1 2026 R&D was $41.5M (up $18.1M YoY, $15.2M of which was DT120), G&A $17.7M (up $8.9M YoY), net loss $77.1M (vs $23.3M), a $20.0M mark‑to‑market warrant impact tied to a share price rise from $13.39 to $18.90, cash and investments of $373.4M supporting runway into 2028, market sizing noted ~4.2M U.S. adults with ≥2 prior treatment failures and a 1% TAM capture modeled as ≈$2B annual revenue, operationally aiming for a 5–8 hour patient journey (vs 10–12 in Phase II) with a single in‑person monitor supported by remote backup, and a potential DEA scheduling acceleration that could shave roughly 90 days from post‑approval access.

Late-Stage Clinical Progress — Multiple Phase III Readouts Imminent

DT120 ODT advancing with four ongoing Phase III studies across MDD, GAD (Breakthrough Therapy designation), and PTSD expansion planned (HAVEN in 2027). Enrollment complete or nearly complete: EMERGE (MDD) = 149 participants (enrollment complete), VOYAGE (GAD) = 214 (complete), PANORAMA (GAD) = exceeded updated target of 200 and expected to complete enrollment this month. Topline timing: EMERGE later this quarter; VOYAGE early Q3; PANORAMA late Q3.

Robust Statistical Power and Study Design

VOYAGE and PANORAMA powered at 99%+ to detect a 5-point placebo-adjusted difference (based on blinded sample size re-estimations). EMERGE powered at 80% to detect a 5-point difference with statistical significance possible at just over a 3-point difference given nuisance parameter assumptions. Primary endpoints staggered (EMERGE: 6 weeks; VOYAGE & PANORAMA: 12 weeks) and Part B follow-up extends to one year with up to four additional open-label treatments to evaluate durability and retreatment patterns.

Strong Liquidity and Runway

Cash, cash equivalents and investments of $373.4 million at quarter-end, which management believes provides runway to fund planned operations through multiple anticipated clinical readouts and into 2028.

Commercial Opportunity and Launch Preparedness

Large addressable market identified (approx. 4.2 million U.S. adults who cycled through ≥2 treatments). Management estimates capturing 1% of TAM (deduplicated for MDD/GAD overlap) using Spravato pricing as a surrogate equates to roughly a $2 billion annual revenue opportunity. Company has a targeted launch plan (high-volume psychiatrists, centralized hub support, payer engagement) and is planning for J-code submission assumptions post-approval.

Investment in Capabilities to Support Potential Commercialization

Deliberate increase in investments to support Phase III execution, NDA preparation, market access, and commercialization readiness. Management describes increased R&D and G&A spending as intentional to prepare for pivotal data and potential launch.

Progress in Non-DT120 Programs (DT402)

Advancing a Phase II DT402 program in autism spectrum disorder (R-enantiomer of MDMA) with promising prosocial signals and a signal-of-efficacy study using patient-, caregiver-, clinician-reported measures and digital behavioral markers.

Operational Improvements — Shorter Patient Journey

Phase III uses an orally dissolving tablet formulation and revised end-of-session criteria to shorten the expected in-clinic patient monitoring window from 10–12 hours in Phase II toward a 5–8 hour target in Phase III, potentially improving clinic throughput and patient experience.

Gita Jain

Good afternoon. I am Gita Jain, Head of Investor Relations, and thank you for joining us today for Mind Medicine (MindMed) Inc.’s first quarter 2026 financial results and recent highlights conference call. Currently, all participants are in listen-only mode. This webcast is live on the Investors section of Mind Medicine (MindMed) Inc.’s website at definiumtx.com, and a replay will be available after the webcast. Leading the call today will be Robert Barrow, our Chief Executive Officer, who is joined by Daniel Karlin, our Chief Medical Officer, Brandi L. Roberts, our Chief Financial Officer, and Matthew Wiley, our Chief Commercial Officer. During today’s call, we will be making certain forward-looking statements including, without limitation, statements about the potential safety, efficacy, and regulatory and clinical progress of our product candidates, our anticipated cash runway, and our future expectations, plans, partnerships, and prospects. These statements are subject to various risks such as changes in market conditions, and difficulties associated with research and development and regulatory approval processes.

These and other risk factors are described in the filings made with the SEC and the applicable Canadian securities regulators including our Annual Report on Form 10-K and our Form 10-Q filed today. Forward-looking statements are based on assumptions, opinions, and estimates of management at the date the statements are made, including the nonoccurrence of the risks and uncertainties that are described in the filings made with the SEC and the applicable Canadia...

Subscribe to unlock transcripts

Get The Fly Pro 7 days for free

Your privacy matters

Search...

Dashboard

Charting

KPIs

Stock Screener

ETF Screener

Earnings Calendar

Events Calendar

Syndicate

Street Research

Portfolios

Alert Settings

Definium Therapeutics

· DFTX

Dashboard

Financials

Ratios

Transcripts

Valuation

May 7th, 2026

Summary

Earnings Call Sentiment

Company Guidance

Late-Stage Clinical Progress — Multiple Phase III Readouts Imminent

Robust Statistical Power and Study Design

Strong Liquidity and Runway

Commercial Opportunity and Launch Preparedness

Investment in Capabilities to Support Potential Commercialization

Progress in Non-DT120 Programs (DT402)

Operational Improvements — Shorter Patient Journey

Gita Jain

Earnings Call Transcripts:

Q1 '26

Q4 '25

Q3 '25

Q2 '25

Q1 '24

Q3 '23

Q2 '23